Facilitating the Development of Advanced Therapies
The European Medicines Agency’s (EMA) Committee for Advanced Therapies (CAT) and the International Society for Cellular TherapyExternal link icon (ISCT) are organising a workshop to discuss how to facilitate the development of advanced therapies on 25 September 2015 in Seville, Spain.
Under the title Challenges and Opportunities for the Successful Development and Approval of Advanced Therapy Medicinal Products (ATMPs), the workshop will bring together academics, developers and regulators for an open discussion on the requirements for a successful development of advanced therapies. Participants will get practical advice on the European authorisation procedure for advanced therapies and the tools and support available to them.
Every year, EMA teams up with an international learned society to organise a workshop in one of the EU Member States. This is an opportunity for the Agency to reach out to academic researchers and small and medium-sized enterprises to explain the regulatory framework for these innovative medicines and the development support the Agency offers.
The workshop will give attendees the opportunity to interact directly with regulators in an open forum discussion and learn more about
• quality development, manufacturing issues and non-clinical testing of ATMPs
• specificities of clinical development of ATMPs
• approval mechanism and EMA support available to ATMP developers
• new EU clinical trial regulation.
The deadline for registration is 18 September 2015. For further information on the workshop and how to register, please see the ISCT Europe 2015 website.
Related News
-
News PSCI Welcomes Delpharm, Samsung Biologics, and Suven as First Supplier Partners
The pharmaceutical industry continues to evolve with an increasing focus on responsible sourcing, sustainability, and collaboration across the supply chain. Under a new model to recognise suppliers within the pharmaceutical and healthcare industry that... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
News Eli Lilly's weight loss drugs removed from the FDA's shortage list
The US FDA have recently updated their drug shortage list. The recently released list shows that all dosage forms of Eli Lilly's weight-loss drug Zepbound and their diabetes drug Mounjaro are now available. -
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance